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Abstract
Objectives
Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern
Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB
and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV
coinfected patients in EE, Western Europe (WE) and Latin America (LA).
Design and Methods
Between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19
countries in EE, WE, Southern Europe (SE), and LA) were enrolled.
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Results
Significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164),
and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72%
and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination
antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use
(adjusted OR (aOR) = 2.03 (95% CI 1.00–4.09), prior anti-TB treatment (3.42 (1.88–6.22)),
and living in EE (7.19 (3.28–15.78)) were associated with MDR-TB. Among 585 patients
with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST
results) anti-TB treatment included3 active drugs in 66% of participants in EE compared
with 90–96% in other regions (p<0.0001).
Conclusions
In EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to
house MDR-TB and commonly received empiric anti-TB treatment with reduced activity.
Improved management of TB/HIV patients in EE requires better access to TB diagnostics
including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and
more widespread use of cART.
Introduction
The incidence of newly diagnosed HIV infections continues to increase in Eastern Europe
(EE), whereas it has decreased in many other regions of the world [1, 2]. The situation in EE is
complicated by nearly 50% of the HIV-positive patients being diagnosed at a time where HIV
treatment should have been initiated (i.e. CD4<350 cells/mm3 or with clinical disease) and by
suboptimal access to combination antiretroviral therapy (cART) [3].
Incidences of tuberculosis (TB) in EE are approximately 100 new cases per 100 000 per year
in countries such as Russia, Belarus, and Latvia, and the prevalence of HIV coinfection is esti-
mated to be 5–19% [4]. TB in HIV-positive individuals poses a diagnostic challenge in terms of
lower sensitivity for smear microscopy, atypical chest radiographic appearances, and frequent
extra-pulmonary localisation. TB treatment also poses a challenge due to long term high pill-
burden regimens, interactions between TB medication and cART, overlapping toxicity and
adherence issues, and especially in EE, high rates of multi-drug resistant TB (MDR-TB),
concurrent hepatitis C coinfection, and injecting drug use (IDU) [5–7]. The prevalence of
MDR-TB and extensively drug-resistant TB (XDR-TB) is particularly high, and still increasing,
in EE and Central Asia [4, 8, 9]. Proportions of MDR-TB have been reported ranging from 12–
35% in new TB cases to 32–77% in retreatment cases in Latvia, Russia and Belarus [6, 8, 10].
Treatment of MDR-TB and XDR-TB is both complicated and costly, and associated with high
morbidity and mortality [11–14]. The extent of TB and HIV coinfection in EE is probably
underestimated as many countries in this region have suboptimal diagnostic services and sur-
veillance systems for both TB and HIV, including data on anti-TB drug resistance [8].
A previous study from our group found a three-to-five fold higher mortality among TB/
HIV coinfected patients in EE compared to patients fromWestern Europe (WE) and Argen-
tina. The current study builds on these previous findings and focuses on assessing potential
changes over time in TB/HIV management [15]. For this analysis, we aimed to study clinical
characteristics of TB/HIV patients in Europe and Latin America (LA) at TB diagnosis, identify
TB/HIV Patients in Eastern Europe
PLOS ONE | DOI:10.1371/journal.pone.0145380 December 30, 2015 2 / 17
established consisting of proposers, members of the
Steering Committee and staff at the coordinating
center and the statistical center. The TB:HIV Study
can be accessed at www.chip.dk/TBHIV, where all
relevant documents are available (study protocol,
CRF’s, newsletters, presentations and publications
etc.). All relevant staff involved in the study and their
contact information is also available at this website.
For submission of research proposal, please contact
Anne Marie Werlinrud Efsen (anne.marie.werlinrud.
efsen@regionh.dk and Ole Kirk (ole.kirk@regionh.
dk).
Funding: This study was funded by the European
Union 7th Framework (FP7/2007-2013, EuroCoord n
° 260694) programme and The Danish Council for
Independent Research (DFF); Research Council,
Copenhagen University Hospital, Rigshospitalet. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: AMW reports a personal grant
from University Hospital Copenhagen. AS reports
grants and travel support from University College
London. HF reports consultancy fees from ViiV,
Gilead, Abbvie, MSD, Jannsen, BMS and grants from
ViiV, Gilead, AbbVie, Roche, Boehringer, MSD, BMS,
Janssen outside the submitted work. RM reports
payment for lectures from ViiV, Merck, Gilead and
Janssen outside the submitted work. JMM reports
consultancy fees from Abbvie, Novartis, payment for
lectures from Abbvie, Bristol-Myers Squibb, Gilead
Sciences, Merck and Novartis y ViiV Healthcare and
grants from Cubist, Gilead, ViiV Healthcare, Novartis,
Merck, Fondo de Investigaciones Sanitarias - Instituto
de Salud Carlos III, Fundación para la Investigación y
Prevención del Sida en España, Ministerio de
Sanidad, Servicios Sociales e Igualdad, National
Institutes of Health and NEAToutside the submitted
work. EG reports board membership for Janssen-
Cilag, consultancy fees from Abbot-Diagnostics,
payment for lectures from BMS, ViiV Healthcare,
Jannsen and grants from Gilead Sciences outside the
submitted work. JT reports grants from EuroCoord
and University of Buenos Aires, CICAL during
conduct of the study. MHL reports grants from
EuroCoord, employment from University of Buenos
Aires, Hospital JM Ramos Mejia, CICAL and grants
from NIH, University of Minnesota, University of New
South Wales, travel fees from Gador outside the
submitted work. AM reports speaker fees, travel fees
and honorarium from BI, Gilead, Pfizer, Merck and
BMS outside the submitted work. OK reports board
membership from Gilead, Merck, ViiV, consultancy
fees from Gilead, payment for lectures from Abbott,
Gilead, Tibotec, travel fees from Abbott, BMS, Gilead,
Merck, ViiV and grants from Bristol-Myers Squibb,
factors associated with MDR-TB, and assess the activity of empiric anti-TB treatment regimens
in relation to subsequent drug-susceptibility test (DST) results [16].
Methods
Study design and participants
The TB:HIV study is a prospective, observational, cohort study of TB/HIV co-infected patients
aged 16 or older who were diagnosed with TB between January 1, 2011, and Dec 31, 2013, at 62
clinics in 19 different countries throughout Europe and LA (see acknowledgements). Partici-
pating sites were chosen on the basis of our previous retrospective TB:HIV collaboration on
patients diagnosed in the period 2004–2006 [15]. The study protocol follow-up (FU) period is
24 months in order to analyse long-term outcome of TB disease. Here, we present analyses
conducted on baseline data.
Procedures
Data were collected on standardised case report forms (CRFs) which included demographics
and information on clinical information on the TB diagnostic work up, initial anti-TB treat-
ment, and baseline TB drug resistance. In addition, CD4 cell counts, HIV-RNA measurements,
ART history, hepatitis B and C status, AIDS defining diagnoses, and malignancies were col-
lected (www.chip.dk under TB:HIV study).
For comparative analyses, centers were divided into 4 different regions; EE (21 clinics in
Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia), WE (19 clinics
in Belgium, Denmark, France, Switzerland, United Kingdom), Southern Europe (SE, 9 clinics
in Italy and Spain), and Latin America (LA, 13 clinics in Argentina, Chile, and Mexico). Clinics
in WE, SE, and LA were included to compare EE with other European regions and another
middle-income region, LA. Baseline was the date of TB diagnosis, defined as the date when TB
treatment was initiated or when the first positive sample forMycobacterium tuberculosis (Mtb)
was obtained, whichever occurred first. TB diagnoses were classified as definite (positive cul-
ture or PCR forMtb), probable (acid fast bacilli or granulomatous inflammation on sputum
smear or tissue biopsy specimens), or presumptive (TB treatment initiated and not subse-
quently stopped because the TB diagnosis was excluded). Pulmonary TB was defined as TB
localised to the lungs, larynx, or tracheobronchial tree. Extra-pulmonary TB was defined as TB
localised to a single organ system (excluding lungs) and disseminated TB was defined as i) TB
documented in at least two organ systems (one of which could be lungs), ii) miliary TB, or iii)
isolation ofMtb from blood or bone marrow. MDR-TB and XDR-TB were defined according
to WHO standard definitions [4].
TB treatment was categorised as RHZ-based (containing at least a rifamycin (R), isoniazid
(H), and pyrazinamide (Z)) or other. Baseline resistance data were based on the first DST sam-
ples taken within one month of the baseline date.
To assess the activity of the empiric anti-TB treatment regimens, we identified the number
of anti-TB drugs to which the patient’sMtb isolate was subsequently found to be susceptible.
All patients with DST results of cultures obtained within one month of their anti-TB treatment
start date were included in this analysis; subsequent adjustments to treatment after DST results
became available were not analysed. If a specific DST result was not available for a given drug,
the patient was assumed to be sensitive to this drug in the primary analysis. We also assessed
the hypothetical number of active drugs if all individuals were modelled as having initiated
empiric therapy with RHZ plus ethambutol (E). In sensitivity analyses, we (1) calculated an
alternative worst-case scenario, where missing DST results for a given drug where recoded as
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resistant and (2) restricted the descriptions to patients with complete resistance results (DST
results available for all anti-TB drugs used in the empiric treatment regimen).
Statistical methods
Variables of interest were stratified according to region and differences tested formally using
the Kruskal-Wallis (continuous variables) or Chi-squared (proportions) tests. Logistic regres-
sion was used to identify risk factors associated with MDR-TB. Variables of interest were
included in the multivariable model based on clinical plausibility and/or previous observations
[14]. Details of the categorization of variables for the multivariable model are shown in the web
appendix, in accordance with STROBE guidelines [17].
In order to compare results from the current analysis to findings from the retrospective
HIV/TB study, data were re-analysed using the present study definitions [15]. Variables rele-
vant for this comparison were decided upon a priori, and proportions compared using a z-test.
All statistical analyses were performed using SAS (Statistical Analysis Software, Cary, NC,
USA, version 9.3).
Ethical approvals
Data were obtained from the patients’medical records or through database exchange using
HICDEP format (www.hicdep.org). The study includes clinics (N = 62) and participants across
many European countries, and each participating site has a contractual obligation to ensure
that data collection and sharing is done in accordance with national legislation; each site princi-
pal investigator either maintains appropriate documentation from an ethical committee (if
required by law) or has a documented written statement to say that this is not required. Fur-
ther, the coordinating center (CHIP) holds written copies of the participating sites ethical
approvals. In specific, the study obtained ethics approval and participants gave informed con-
sent before taking part:
Le Comité d’Ethique du C.H.U Saint-Pierre, Le Numéra registre AK/12-03-28/4128, Comité
Ético Cientifico del servicio de Salud Metropolitano Centra, Chil, certificado 452/11, De
Videnskabsetiske Komiteer i Region Hovedstaden Journal nr.: H-3-2011-095, United Kingdom
national ethics approval Reference nr. 11/LO/0713 & R&D Reference nr. CSP 75430 for UK
sites: Mortimor Market Centre, London, Imperial College Healthcare, London, St. Marys Hos-
pital, London, North Manchester General Hospital, Manchester, Sheffield Teaching Hospitals,
Sheffield, King´s College Hospital, London, North Middlesex University Hospital, London,
Queen Elisabeth Hospital, London R&D ref. nr. SLHT/2011/UCSM/HIV/88, Leicester Royal
Infirmary, Leicester. El Comité de Etica en Investigación en Salud, Hospital Paroissien Argen-
tina 20/12/2911, Comité de Etica Iniciativa y Reflextion Bioetica Hospital Pineiro & Hospital
Ramos Mejia Argentina 12/12/12, Comité de Bioética Reg. nr. 11743/11 Hospital Nacional
Profesor Alejandro Posdas Argentina, Comité Institucional de Ètica de la Investigacion en
Salud del Nino u del Adulto Cordoba 16/12/2012 Hospital Rawson, Comité de Etica La Plata
12/11/12 Hospital Sa Juan de Dios Argentina, Comité de Ética en Investigacion Buenos Aires
18/11/12 Hospital Santojani Argentina & 11/05/2012 Hospital Fracisco Javier Muniz Argen-
tina, Docencia e Investigación 15/06/12 Jujuy Argentina, Institutional Review Board Tbilisi
Ref. nr. 12–007, Registro delle Sperimentazioni del Comitato Etico Rone nr. 24/2011 Spallan-
zani, Comitato Etico San Gerardo, Monza 26/05/2011, Comitato Etico Aziendale A.O.U. San
Martino Genoa nr. 295 08/04/2011, Comitato Etico Indipendente Locale Policlinio Consorziale
Bari nr. 624 28/09/2011, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Ref. nr 437, Comité de Ética del Hospital General Regional de León 10/10/2011, Secretario del
Comité de Ensenanza, Investigacion y Ética Hospital Civil de Guadalajara Invest. Nr. 038/12,
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Comitato Etico Spedali Civili Brescia 07/06/2011 nr.36; Direcció General de Regularcio Barce-
lona CY-ANT-2011-01, Hospital Universitario Ramón y Cajal Comité Ético de Investigación
Clinica 12/07/2011, Comite Etico de Investigation Clinica de Euscadi Vitoria 02/02/2012,
Comité Ético de Investigación Clínica Hospital General Universitario Gregorio Maranon
Madrid SAS/3470/2009, Kantonale Ethik-Kommission Zürich EK-793, Ethical Committee of
Rep. Res. And Practical Centre for Pulmonology Minsk 11/02/2011, Ethical Committee of
Gomel State Medical University & Gomel Regional Centre for Hygiene, Ethical Committee for
Botkin Hospital & City TB Hospital ref. nr.23, Ethical Committee for Novgorod Centre for
AIDS Prevention and Control 11/10/2011, Ethican Committee of Samara State Medical Uni-
versity 10/10/2012, Komisja Bioetycznego Uniwersytetu Medycznego w Bialymstoku Poland
R-I-00/85c/2012 –R-I-002/85/2011, Tallinn Medical Research Ethics Committee Appr. Nr.
2555, RSU Etikas Komitejas Lemums Riga Nr. E-9(2), Vilniaus Regioninis Biomedicininiu Tyr-
imu Etikos Komitetas Nr. 158200-07-363-90, Dr. Victor Babes Hospital Institutional Ethics
Committee nr. 3889, Ethics Committee Crimean Republican AIDS Centre Nr. 462-13-08-12.
Results
A total of 1413 patients were enrolled (Table 1). The majority of patients (72.5%) were male,
with a median age of 36 years and a median CD4 cell count of 113 cells/mm3. Although the
HIV diagnosis preceded the TB diagnosis by more than 3 months in 69% of participants, only
27% had ever received cART. More than half of all patients had disseminated TB, and 14%
reported a prior episode of TB. We observed large regional variation in patient characteristics,
with participants in EE more commonly reporting a history of IDU, recent incarceration, and
more likely to be co-infected with hepatitis C and naïve to cART. Patients in both EE and LA
were more likely to originate from the same country as they were being treated in and patients
who inject drugs were less likely to have access to opioid substitution therapy (Table 1).
The TB diagnosis was definite in approximately half of all patients, and the empiric anti-TB
treatment contained RHZ in 78%. In both EE and LA, fewer patients had a definite TB diagno-
sis (47% and 40%, respectively, vs. 71% and 72% inWE and SE, respectively) and fewer patients
in EE received empiric RHZ-containing anti-TB regimens (Table 2). Overall, 569 patients
(40% of all patients, 79% of those with definite TB) had anti-TB DST performed within one
month of baseline. The proportion of patients with definite TB who had DST performed was
lower in EE (73% vs. 83–89%), and the prevalence of R or H resistance and MDR-TB was nota-
bly higher in EE (41%, 51% and 40%, respectively, of those tested) compared with other Euro-
pean regions (<10%). In LA, relatively high rates of R or H resistance and MDR-TB were
encountered (18%, 25% and 15%, respectively, of those tested). The proportion of patients with
no documented resistance was lower in EE (43%) compared with 89–91% in WE and SE and
74% in LA. In both EE and LA, less than half ofMtb isolates were tested for pyrazinamide and
ethambutol resistance, and streptomycin resistance was widespread (Table 2). Of the 97 docu-
mented MDR-TB cases in EE, 27 (39.1% of 69 tested) were also resistant to kanamycin, amika-
cin, or capreomycin, 18 (27.7% of 65 tested) to fluoroquinolones, and 7 (14.3% of 49 tested)
were XDR-TB. In multivariable models, receiving care in EE (aOR 7.2 [95% CI 3.3–15.8]),
prior anti-TB treatment (aOR 3.4 [95% CI 1.9–6.2]) and history of IDU (aOR 2.0 [1.0–4.1])
were all significantly associated with MDR-TB (Fig 1).
Overall, only 17 (1%) did not start anti-TB treatment and 1329 (95%) started treatment
within 30 days of baseline. The majority of patients initiated anti-TB treatment containing at
least RHZ (78%), however, this varied substantially across regions; from 71% in EE to 90% in
LA; p<0.0001 (Table 2). Of these patients, the majority initiated standard treatment with RHZ
TB/HIV Patients in Eastern Europe
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Table 1. Demographic and clinical characteristics of the study population.
characteristics of the study population
Total Eastern Europe Western
Europe
Southern
Europe
Latin America
N (%) N (%) N (%) N (%) N (%) P-
value
Total 1413 (100) 844 (100) 152 (100) 164 (100) 253 (100)
Gender Female 389 (27.5) 210 (24.9) 67 (44.1) 45 (27.4) 67 (26.5) < .0001
Ethnicity1 White 971 (71.2) 773 (95.2) 39 (26.2) 112 (72.3) 47 (19.0) < .0001
Black African 123 (9.0) 0 (0) 94 (63.1) 27 (17.4) 2 (0.8)
Hispanic 189 (13.9) 0 (0) 4 (2.7) 8 (5.2) 177 (71.4)
Other 81 (5.9) 39 (4.8) 12 (8.1) 8 (5.2) 22 (8.9)
Age Years, median (IQR) 36 (31–43) 35 (31–40) 37 (32–48) 42 (33–48) 38 (30–45) < .0001
Origin2 Country of origin same as
centre
1156 (83.4) 828 (99.4) 20 (13.9) 81 (49.7) 227 (92.3) < .0001
Other European country 38 (2.7) 2 (0.2) 15 (10.4) 19 (11.7) 2 (0.8)
Any other country 192 (13.9) 3 (0.4) 109 (75.7) 63 (38.7) 17 (6.9)
Weight3 Kg, median (IQR) 60 (53–68) 60 (53–68) 62 (53–67) 59 (54–70) 59 (50–70) 0.61
Hepatitis B4 HBsAg positive [current or
previous]
76 (8.4) 48 (8.8) 11 (10.8) 8 (7.0) 9 (6.3) 0.57
HBsAg tested—negative 830 (91.6) 498 (91.2) 91 (89.2) 107 (93.0) 134 (93.7)
Hepatitis C5 HCV Ab positive [current or
previous]
510 (54.0) 421 (74.4) 21 (19.6) 41 (34.5) 27 (17.7) < .0001
HCV RNA positive 67 (4.7) 19 (2.3) 18 (11.8) 24 (14.6) 6 (2.4)
HCV Ab tested—negative 435 (46.0) 145 (25.6) 86 (80.4) 78 (65.6) 126 (82.4)
HIV Risk
Group 6
MSM 137 (10.2) 12 (1.5) 16 (10.8) 29 (18.2) 80 (32.3) < .0001
IDU 589 (43.7) 502 (63.5) 9 (6.1) 45 (28.3) 33 (13.3)
Heterosexual 453 (33.7) 206 (26.0) 84 (56.8) 44 (27.7) 119 (48.0)
Other 167 (12.4) 71 (9.0) 39 (26.4) 41 (25.8) 16 (6.5)
HIV disease HIV+ >3 months before TB
diagnosis7
973 (68.9) 635 (75.2) 82 (54.0) 99 (60.4) 157 (62.1) < .0001
CD4 count median (IQR)
(cells/mm3) 8
113 (36–275) 107 (35–254) 149 (35–360) 129 (38–315) 96 (35–289) 0.12
RNA median (IQR) (log10
copies /ml) 9
115E3 (2586 -
497E3)
165E3 (21500 -
538E3)
61000 (96 -
37E4)
49162 (213 -
443E3)
49600 (132 -
353E3)
< .0001
Prior or Current AIDS 377 (26.7) 198 (23.5) 25 (16.5) 50 (30.5) 104 (41.1) < .0001
HIV treatment Naïve 1027 (72.7) 693 (82.1) 89 (58.6) 89 (54.3) 156 (61.7) < .0001
cART 361 (25.6) 140 (16.6) 60 (39.5) 72 (43.9) 89 (35.2) < .0001
TB Risk
Group
IDU 616 (43.6) 516 (61.1) 14 (9.2) 48 (29.3) 38 (15.0) < .0001
In prison in last 2 years 186 (13.2) 157 (18.6) 4 (2.6) 8 (4.9) 17 (6.7) < .0001
Alcohol misuse 306 (21.7) 202 (23.9) 12 (7.9) 19 (11.6) 73 (28.9) < .0001
TB cases in the family 125 (8.9) 62 (7.4) 9 (5.9) 11 (6.7) 43 (17.0) < .0001
Travel/Migration 100 (7.1) 2 (0.24) 64 (42.1) 29 (17.7) 5 (2.0) < .0001
Other risk factor 156 (11.0) 34 (4.0) 16 (10.5) 21 (12.8) 85 (33.6) < .0001
None indicated 335 (23.7) 183 (21.7) 49 (32.2) 60 (36.6) 43 (17.0) < .0001
TB Type Pulmonary 458 (32.4) 303 (35.9) 27 (17.9) 52 (31.7) 76 (30.2) < .0001
Extrapulmonary 194 (13.7) 59 (7.0) 37 (24.5) 38 (23.2) 60 (23.8)
Disseminated 758 (53.8) 481 (57.1) 87 (57.6) 74 (45.1) 116 (46.0)
TB in the
past10
Yes 187 (13.8) 111 (13.4) 14 (10.1) 21 (14.5) 41 (16.5) 0.36
(Continued)
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plus ethambutol (E); ranging from 70% in EE to 94% in LA. Similar trends were found when
restricting analyses to patients without a history of prior TB (data not shown).
In Fig 2, intraregional differences in the use of RHZ-based empiric anti-TB treatment are
shown in relation to the observed MDR-TB prevalence. We observed substantial variation in
the prevalence of MDR-TB in EE, ranging from 11–56% between countries with considerable
uncertainty in some countries due to the small numbers of patients. The proportion of partici-
pants who initiated RHZ-based empiric anti-TB treatment appeared similar in most countries
across the four regions with the exception of two countries in EE where 54% and 74% (95% CI
48–86%) of patients received such therapy. The country in which the smallest proportion of
patients received RHZ-based therapy reported among the highest prevalence of MDR-TB
(40%, 95% CI 24–58%). There was no evidence of a correlation between the country-wise pro-
portions of patients initiating RHZ-based treatment and prevalences of MDR-TB (p = 0.30
and p = 0.50 for EE andWE, respectively; analysis restricted to regions with at least three data
points).
For patients with DST results available, we next calculated the average number of active
drugs used in the empiric anti-TB treatment regimen in relation to the subsequent DST results.
The proportion of participants who received treatment with at least three active drugs ranged
from 66% in EE to 90–96% in the other regions, p<0.0001, Fig 3a). Worryingly, the empiric
regimen contained one or two active drugs in 25% of patients in EE, and no active drugs at all
in 9%. These results did not change in sensitivity analyses restricted to individuals with full
resistance profiles available. We next assumed resistance to all drugs for which no DST data
were available, and the proportion receiving empiric therapy with at least three active drugs
ranged from 32% and 39% in LA and EE to 75–80% in the other regions, p<0.0001, underlin-
ing that a full DST report was not available for many patients in EE and LA. Routine use of
Table 1. (Continued)
characteristics of the study population
Total Eastern Europe Western
Europe
Southern
Europe
Latin America
N (%) N (%) N (%) N (%) N (%) P-
value
Total 1413 (100) 844 (100) 152 (100) 164 (100) 253 (100)
No 1172 (86.2) 716 (86.6) 124 (89.9) 124 (85.5) 208 (83.5)
Current
OST11
Yes 43 (8.5) 16 (3.7) 6 (66.7) 21 (48.8) 0 (0) < .0001
No 465 (91.5) 413 (96.3) 3 (33.3) 22 (51.2) 27 (100.0)
1 49 individuals had missing ethnicity.
2 27 individuals had missing data on origin.
3 785 individuals had missing data on weight.
4 507 individuals had missing data on Hepatitis B.
5 468 individuals had missing data on Hepatitis C.
6 67 individuals had missing data on risk group. MSM = Men who have sex with men. IDU = Intravenous drug use.
7 1220 (86.34%) individuals were known to be HIV-positive at baseline.
8 204 individuals had missing baseline CD4 values.
9 490 individuals had missing baseline RNA values.
10 54 individuals had missing data on TB in the past.
11 OST = Opioid Substitution Therapy. The denominator is IDU (HIV) risk group. 81 individuals (of those who were IDU’s) had missing data on OST
status.
doi:10.1371/journal.pone.0145380.t001
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RHZE as the empiric anti-TB regimen would have had minimal impact on the proportion of
patients who received at least three active drugs in all regions (Fig 3b).
We compared the data from the present study with our findings from the retrospective TB:
HIV study (S1 Table). The overall number of patients on cART at baseline increased signifi-
cantly from 11% to 26% (p<0.0001), the proportion of patients who initiated RHZ-containing
empiric anti-TB treatment increased from 62% to 78% (p<0.0001), as did the proportion of
patients diagnosed with resistance to R. The observed increases in use of RHZ-based anti-TB
treatment andMtb drug-resistance were largely driven by EE (data not shown). Similar results
were obtained when the analysis was restricted to clinics that participated in both studies.
Table 2. TB diagnostic status, empiric treatment regimens and drug resistance patterns.
Total Eastern
Europe
Western
Europe
Southern
Europe
Latin America
N (%) N (%) N (%) N (%) N (%) P-
value
Diagnosis Deﬁnite1 722 (51.1) 395 (46.8) 108 (71.1) 118 (72.0) 101 (39.9) < .0001
Probable 226 (16.0) 115 (13.6) 12 (7.9) 9 (5.5) 90 (35.6)
Presumptive 465 (32.9) 334 (39.6) 32 (21.1) 37 (22.6) 62 (24.5)
Treatment2 RHZ based 1091 (78.2) 592 (71.3) 132 (87.4) 140 (86.4) 227 (89.7) < .0001
3 drugs- RHZ only 32 (2.9) 16 (2.7) 2 (1.5) 12 (8.6) 2 (0.9) < .0001
4 drugs- RHZ + E 868 (79.6) 416 (70.3) 118 (89.4) 120 (85.7) 214 (94.3) < .0001
4 drugs- RHZ + S 53 (4.9) 52 (8.8) 0 (0) 0 (0) 1 (0.4) < .0001
4 drugs- RHZ + other 34 (3.1) 29 (4.9) 2 (1.5) 3 (2.1) 0 (0) < .0001
5 drugs- RHZ + ES 61 (5.6) 57 (9.6) 0 (0) 2 (1.4) 2 (0.9) < .0001
5 drugs- RHZ + other 43 (3.9) 22 (3.7) 10 (7.6) 3 (2.1) 8 (3.5) < .0001
Not RHZ based 305 (21.9) 238 (28.7) 19 (12.6) 22 (13.6) 26 (10.3)
Resistance Tested 569 (40.3) 288 (34.1) 92 (60.5) 105 (64.0) 84 (33.2) < .0001
None detected3 363 (63.8) 123 (42.7) 82 (89.1) 96 (91.4) 62 (73.8) < .0001
Tested for at least RH4 Susceptible to RH 303 (66.0) 117 (48.2) 60 (90.8) 81 (91.0) 45 (73.7) < .0001
R resistant/H
susceptible
5 (1.1) 2 (0.8) 0 (0) 0 (0) 3 (4.9) 0.02
H resistant/R
susceptible
39 (8.5) 27 (11.1) 3 (4.6) 5 (5.6) 4 (6.6) 0.004
Resistant (MDR-TB) 112 (24.4) 97 (39.9) 3 (4.6) 3 (3.4) 9 (14.8) < .0001
N/N Tested
(%)
N/N Tested
(%)
N/N Tested (%) N/N Tested (%) N/N Tested
(%)
P-
value
Resistance to speciﬁc
drugs
Rifamycins (R) 126/496 (25.4) 105/259 (40.5) 5/71 (7.0) 3/93 (3.2) 13/73 (17.8) < .0001
Isoniazid (H) 163/506 (32.2) 132/259 (51.0) 6/81 (7.4) 8/99 (8.1) 17/67 (25.4) < .0001
Pyrazinamide (Z) 45/325 (13.9) 34/131 (26.0) 1/81 (1.2) 2/73 (2.7) 8/40 (20.0) < .0001
Ethambutol (E) 81/454 (17.8) 74/233 (31.8) 2/81 (2.5) 1/95 (1.1) 4/45 (8.9) < .0001
Streptomycin (S) 104/194 (53.6) 95/148 (64.2) 2/6 (33.3) 1/22 (4.6) 6/18 (33.3) < .0001
1 Only 25 (3.5%) of those with a deﬁnite diagnosis were diagnosed by PCR alone.
2 17 individuals lacked anti-TB treatment data and were excluded from the descriptions of empiric anti-TB treatment regimens. 14 of these (82.35%) came
from Eastern Europe. This means that the denominator is the remaining 1396 individuals.
3 The denominator is everyone with a resistance test at baseline.
4 Of those with a resistance test, 506 (88.9%), 496 (87.2%) and 459 (80.7%) were tested for H and R and MDR-TB resistance, respectively. The
denominator for these categories is the 459 individuals tested for at least RH.
doi:10.1371/journal.pone.0145380.t002
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Discussion
The present study documents major challenges in EE, and in our cohort more than half of the
patients in EE did not have a definite TB diagnosis, approximately two thirds had no DST
available and among those with a DST available, over one third had suboptimal activity of the
empiric anti-TB regimen.
Levels of MDR-TB among patients from EE in our cohort are alarmingly high and appear
to have increased compared to the 2004–2006 cohort, although our cohort was not designed to
address time-trends in resistance prevalence [15]. In agreement with our findings, other studies
have reported similarly high and increasing prevalence of MDR-TB in Belarus, Latvia and Rus-
sia [6, 10, 13, 18]. The strongest risk factor for MDR-TB in the present study was residence in
EE, and the adjusted odds of having MDR-TB remained seven times higher compared to other
regions. IDU and having received previous anti-TB treatment were also significantly associated
with having MDR-TB, the latter being consistent with previous findings [19–21].
We found that low proportions of patients had a confirmed TB diagnosis and DST results
available in both LA and EE. However, as the proportion of patients with MDR-TB was sub-
stantially lower in LA compared to EE, the majority of patients in LA were likely to have
been treated for their TB disease with at least three active drugs while a large proportion of
Fig 1. Factors associated with MDR-TB in multivariable logistic regression analysis.
doi:10.1371/journal.pone.0145380.g001
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participants in EE received inadequate treatment regimens. These results emphasize the need
for improved diagnostic facilities and laboratory capacity as a political and public health prior-
ity, particularly in the Eastern European region [22]. Additionally, of those patients from EE
who had a DST available, only half with MDR-TB were additionally tested for XDR-TB. Rapid
identification of patients infected with R resistant strains, a surrogate marker for MDR-TB,
would allow for “up-front” adjustment of anti-TB treatment and thereby providing clinicians
the opportunity to initiate a more accurate and effective treatment regimen. The WHO recom-
mends that the Xpert MTB/RIF test, an automated molecular test forMtb and resistance to R,
should be used as the initial diagnostic test in individuals suspected of having MDR-TB or
HIV-associated TB [23]. Early detection of MDR-TB is essential to reduce death rates, lower
spread and prevent further development of drug resistance including development of XDR-TB,
and the Xpert MTB/RIF test has been shown to be particularly effective in HIV-positive
patients who more often present with smear-negative disease [24].
There are no current guidelines on specific empiric anti-TB treatment regimens in areas
with high levels of anti-TB drug resistance. The World Health Organization recommends that
empiric treatment includes a combination of the most potent anti-TB medication based on
expert knowledge of local resistance patterns [25]. Three active drugs are generally considered
as the minimum acceptable number of drugs to treat active TB disease [26, 27]. In our study,
78% of patients with a DST performed at baseline (and thus with DST results unavailable at
time of initiation of the empiric treatment regimen) were initiated on anti-TB treatment with
at least three drugs to which the patient’sMtb isolates were subsequently not found to be
Fig 2. Proportion (95% CI) receiving RHZ-based empiric therapy (a) and proportion (95%CI) with MDR-TB (b) in different countries and study
regions. The intraregional differences in the use of RHZ-based empiric anti-TB treatment are shown in relation to the observed MDR-TB prevalence.
doi:10.1371/journal.pone.0145380.g002
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resistant. In EE, around one third of the patients started less than three active drugs as part of
the empiric therapy. This represents a best-case scenario and if missing resistance data for a
given drug were considered as indicative of resistance to that drug, the situation would be sub-
stantially worse. This finding reflects that for many patients DST was only available for some
drugs and clearly emphasizes the need for accurate and rapidly available diagnostics and DST
results, as suboptimal treatment substantially increases the risk of developing further drug
resistance and is associated with poorer treatment outcomes [24, 28]. Interestingly, calculating
hypothetical scores (presuming RHZE treatment had been initiated in all patients) did not
Fig 3. Susceptibility of empiric anti-TB treatment (a)1 and hypothetical susceptibility presuming RHZE had been initiated (b)2. 1The number of active
drugs for a patient was calculated based on initial anti-TB therapy and DST results within the first month of therapy (available for 585/1396 patients). 2The
number of active drugs in the initial anti-TB treatment regimen, assuming RHZE had been initiated in all subjects (available for 585/1396 patients).
doi:10.1371/journal.pone.0145380.g003
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result in major improvements underscoring that a general recommendation of RHZE regimens
is not the optimal solution in areas with high burden anti-TB drug resistance.
The challenges in EE were further documented when comparing two middle-income
regions, EE and LA. The levels of anti-TB drug resistance were substantially higher in EE, as
was the prevalence of inadequate empiric treatment among patients with a DST. We also
observed large intraregional differences in choice of empiric therapy between countries within
EE, and there was not clear correlation between usage of RHZ-based regimens and the level
of MDR-TB in the individual countries. This highlights the heterogeneity in the treatment
approach within EE and the present results may be used in conjunction with national-level
data from countries in EE in order to inform public health policy and regional/national treat-
ment guidelines.
Only 17% of patients in EE were on cART at time of TB diagnosis despite 75% were both
known to be HIV-positive and most were severely immunosuppressed. This is in line with a
recent report on very limited usage of cART among HIV-positive IDUs living in EE and calls
for urgent actions to retain HIV-positive patients in EE in care and expand access to cART
[29]. In our study, a large proportion of the patients were diagnosed with TB and HIV at pro-
nounced immunodeficiency which is in agreement with results from a recent study reporting
that approximately half of the patients were diagnosed late with HIV in all regions of Europe
(CD4<350/mm3 and/or AIDS events [3]. Early diagnosis of HIV infection allows for timely
initiation of cART as well as preventive therapy for TB, both of which may lead to a reduction
in development of active TB disease [30–32]. Taken together, these results underline the
need to implement strategies to diagnose people living with HIV who remain unaware of their
diagnosis.
Only 4% of IDUs in EE were receiving opioid substitution therapy although this is recom-
mended by the WHO for IDUs infected with TB and HIV, and shown in a smaller observa-
tional study from Ukraine to increase adherence and treatment completion rates [33, 34].
Altogether, an integrated approach to patients is needed, which includes social support and
access to both cART and opioid substitution therapy to ensure FU of patients and ultimately to
improve outcomes [35].
Our study has several limitations. First, it is an observational study with the potential for
selection bias. Secondly, clinics in the various regions were generally located in larger cities and
some countries were only represented by a single clinic. As these clinics may represent centers
of excellence, especially in Eastern Europe, the results presented here do not necessarily reflect
the situation in all clinics in the participating countries, and the situation may well be worse in
Eastern Europe. Further, DST was done at each participating clinic’s laboratory. Generally, a
solid medium (Löwenstein-Jensen) was used for growing mycobacteria, but details on labora-
tory work were not collected and variable methodology may have biased the results. Finally,
full DST results were not available for all patients. Whereas this may impact the analyses, it
also reflects the clinical reality and the decision making for empiric therapy in primarily EE
and LA.
In conclusion, this study documents large regional differences in clinical characteristics, lev-
els of anti-TB drug resistance, and treatment patterns among TB/HIV coinfected patients
throughout Europe and LA. Our findings demonstrate a clear need for improving and imple-
menting more accurate and rapidly available diagnostics and for providing better empiric anti-
TB treatment, particularly in EE. The focus should also be to keep patients under FU and to ini-
tiate cART when appropriate according to guidelines in order to reduce the risk of developing
clinical TB disease. The long-term clinical impact of the present alarming findings will be fur-
ther analysed as follow up data accumulates in this prospective study (www.cphiv.dk under
TB:HIV study).
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